The Break Between Research Contract and Assured Purchase
Can UKDI’s reopened call create a repeatable route from public-safety experiment to assured procurement?
UK Defence Innovation’s reopened Security Open Call, which opened at 12:00 BST on 3 August 2026, can place a fixed-price research contract worth up to £350,000 as a maximum project price exclusive of VAT, take selected work to a demonstration at Technology Readiness Level 6 or 7 and, where an option is exercised, expose it to an operational environment. That ceiling should be read against two figures drawn from the governing documents. The draft Terms and Conditions carry aggregate liability caps of £5 million for specified categories, roughly fourteen times the maximum project value; and the threshold above which the full procurement regime applies to a defence and security contract stands at £415,440 including VAT under PPN 023, within touching distance of the same ceiling grossed up for tax. A maximum research price is therefore neither an accredited product, an approved service nor a funded customer order. The decisive economic question begins after the research contract: who owns the requirement, the test evidence and the residual assurance work; who finances industrialisation, integration and through-life support; and which public body or protected-infrastructure operator holds both the authority and the budget to buy. The question the published documents leave open is not whether a demonstrator can succeed, but who is obliged to act when it does.
The sections that follow work through that chain in order. The first reads the instrument itself against the competition document of 3 August 2026 and the draft Contract Purchase Agreement PA0000004115, and establishes what a firm-price research contract does and does not create. The second traces the institutional separation between the Home Office and the National Protective Security Authority, which define the need, and the Secretary of State for Defence acting through Dstl, which places the contract. The third takes the twenty-three challenge areas of the two published annexes and shows that they do not share an adoption chain. The fourth reads the economics of the ceiling against the payment terms and the liability provisions of the draft agreement. The fifth examines what the optional trial buys. The sixth works through the Procurement Act 2023, the research and development exemption at Schedule 2 paragraph 22 and the prototypes justification at Schedule 5 paragraph 2, using the Cabinet Office guidance on exempted contracts, direct award, frameworks and contract modifications. The seventh addresses rights in the resulting evidence. The eighth maps the assurance regimes. The ninth sets the industrial boundary, and the tenth tests what the predecessor programme’s published record proves, against the National Audit Office’s measurement of how slowly policing adopts what it has already proven. The report does not value any company, assess any supplier and does not identify a winner, because at the research cut-off no Cycle 1 supplier had been published.